Analyst Ratings For Beyondspring Inc (NASDAQ:BYSI)
Today, HC Wainwright reiterated its Buy rating on Beyondspring Inc (NASDAQ:BYSI).
There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Beyondspring Inc (NASDAQ:BYSI) is Buy with a consensus target price of $47.50 per share, a potential 160.70% upside.
Some recent analyst ratings include
- 3/4/2019-Beyondspring Inc (NASDAQ:BYSI) had its Buy rating reiterated by HC Wainwright
- 10/25/2018-Beyondspring Inc (NASDAQ:BYSI) had its Buy rating reiterated by Maxim Group with a $35.00 price target
- 12/5/2017-Beyondspring Inc (NASDAQ:BYSI) has coverage initiated with a Buy ➝ Buy rating and $56.00 price target
About Beyondspring Inc (NASDAQ:BYSI)
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
Recent Trading Activity for Beyondspring Inc (NASDAQ:BYSI)
Shares of Beyondspring Inc closed the previous trading session at 18.03 up +0.15 0.84% with shares trading hands.